Landfar Bio-medicine Co., Ltd. (000504) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Landfar Bio-medicine Co., Ltd.

Why is Landfar Bio-medicine Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 21.96% and Operating profit at -6.75% over the last 5 years

The company has declared Positive results for the last 3 consecutive quarters

NET SALES(HY) Higher at CNY 451.8 MM
NET PROFIT(HY) Higher at CNY 34.71 MM
ROCE(HY) Highest at 16.47%

With ROE of 12.88%, it has a fair valuation with a 9.24 Price to Book Value

Over the past year, while the stock has generated a return of -10.34%, its profits have risen by 229.9% ; the PEG ratio of the company is 0.3

Below par performance in long term as well as near term

Along with generating -10.34% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Landfar Bio-medicine Co., Ltd. should be less than 10%
Overall Portfolio exposure to Retailing should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Landfar Bio-medicine Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Landfar Bio-medicine Co., Ltd.

-15.7%

0.48

37.73%

China Shanghai Composite

19.22%

1.46

13.80%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

21.96%

EBIT Growth (5y)

-6.75%

EBIT to Interest (avg)

-7.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.69

Sales to Capital Employed (avg)

0.52

Tax Ratio

15.27%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

12.39%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

9.24

EV to EBIT

158.56

EV to EBITDA

59.48

EV to Capital Employed

8.17

EV to Sales

5.07

PEG Ratio

0.31

Dividend Yield

ROCE (Latest)

5.15%

ROE (Latest)

12.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company

NET SALES(HY)

Higher at CNY 451.8 MM

NET PROFIT(HY)

Higher at CNY 34.71 MM

ROCE(HY)

Highest at 16.47%

PRE-TAX PROFIT(Q)

At CNY 11.55 MM has Grown at 132.25%

INVENTORY TURNOVER RATIO(HY)

Highest at 11.78 times

DEBTORS TURNOVER RATIO(HY)

Highest at 2.01 times

-20What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY -202.53 MM

RAW MATERIAL COST(Y)

Grown by 66.11% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 16.73 %

INTEREST(Q)

Highest at CNY 2.41 MM

Here's what is working for Landfar Bio-medicine Co., Ltd.

Net Sales

At CNY 451.8 MM has Grown at 600.64%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CNY MM)

Net Profit

At CNY 34.71 MM has Grown at 355.82%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (CNY MM)

Pre-Tax Profit

At CNY 11.55 MM has Grown at 132.25%

over average net sales of the previous four periods of CNY 4.97 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Sales

Higher at CNY 451.8 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (CNY MM)

Net Profit

Higher at CNY 34.71 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Inventory Turnover Ratio

Highest at 11.78 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 2.01 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Landfar Bio-medicine Co., Ltd.

Operating Cash Flow

Lowest at CNY -202.53 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 2.41 MM has Grown at 24.2%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest

Highest at CNY 2.41 MM

in the last five periods and Increased by 24.2% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 16.73 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 66.11% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales